Mark Glover

2.2k total citations · 1 hit paper
23 papers, 1.7k citations indexed

About

Mark Glover is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Mark Glover has authored 23 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Mark Glover's work include Ion Transport and Channel Regulation (13 papers), Electrolyte and hormonal disorders (8 papers) and Hormonal Regulation and Hypertension (6 papers). Mark Glover is often cited by papers focused on Ion Transport and Channel Regulation (13 papers), Electrolyte and hormonal disorders (8 papers) and Hormonal Regulation and Hypertension (6 papers). Mark Glover collaborates with scholars based in United Kingdom, United States and Australia. Mark Glover's co-authors include Stephen C. Harrison, Kevin M. O’Shaughnessy, Anjana Rao, Patrick G. Hogan, Lin Chen, Annie Mercier Zuber, Ciarán Richardson, Fatema H. Rafiqi, Aleksandar Jovanović and Stewart Fleming and has published in prestigious journals such as Nature, Journal of Clinical Investigation and Journal of Medicinal Chemistry.

In The Last Decade

Mark Glover

22 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Crystal structure of the heterodimeric bZIP transcription factor c-Fos–c-Jun bound to DNA

1995 608 citations Mark Glover, Stephen C. Harrison Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Glover United Kingdom	15	1.3k	265	195	168	146	23	1.7k
Douglas Buckley United States	18	831 0.6×	440 1.7×	148 0.8×	203 1.2×	87 0.6×	25	1.8k
Rocio Garcı́a-Becerra Mexico	25	744 0.6×	224 0.8×	166 0.9×	108 0.6×	425 2.9×	74	1.8k
Miki Imanishi Japan	25	1.2k 1.0×	89 0.3×	42 0.2×	158 0.9×	89 0.6×	106	2.1k
Pramod M. Lad United States	25	1.1k 0.9×	95 0.4×	322 1.7×	137 0.8×	123 0.8×	67	2.0k
Ke‐He Ruan United States	23	733 0.6×	84 0.3×	75 0.4×	64 0.4×	110 0.8×	79	1.4k
Sharon M. Louie United States	18	1.1k 0.9×	122 0.5×	132 0.7×	56 0.3×	196 1.3×	23	2.0k
Qiang Xie China	24	759 0.6×	157 0.6×	67 0.3×	32 0.2×	239 1.6×	66	1.5k
Rajesh Ghai Australia	20	869 0.7×	82 0.3×	91 0.5×	108 0.6×	184 1.3×	36	1.5k
Urs Lewandrowski Germany	23	1.0k 0.8×	140 0.5×	142 0.7×	19 0.1×	113 0.8×	35	1.8k
Sutapa Ray United States	26	1.1k 0.8×	149 0.6×	360 1.8×	40 0.2×	419 2.9×	74	2.0k

Countries citing papers authored by Mark Glover

Since Specialization

Citations

This map shows the geographic impact of Mark Glover's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Glover with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Glover more than expected).

Fields of papers citing papers by Mark Glover

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Glover. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Glover. The network helps show where Mark Glover may publish in the future.

Co-authorship network of co-authors of Mark Glover

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Glover. A scholar is included among the top collaborators of Mark Glover based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Glover. Mark Glover is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Faconti, Luca, Spoorthy Kulkarni, Christian Delles, et al.. (2023). Diagnosis and management of primary hyperaldosteronism in patients with hypertension: a practical approach endorsed by the British and Irish Hypertension Society. Journal of Human Hypertension. 38(1). 8–18. 11 indexed citations

Glover, Mark, Cyril M. Kay, M. Joanne Lemieux, & Randy J. Read. (2023). Michael James (1940–2023). Acta Crystallographica Section D Structural Biology. 79(10). 953–955.

Kulkarni, Spoorthy, Mark Glover, Vikas Kapil, et al.. (2022). Management of hypertensive crisis: British and Irish Hypertension Society Position document. Journal of Human Hypertension. 37(10). 863–879. 27 indexed citations

Brown, Chloë, et al.. (2018). PSY93 - COST EFFECTIVENESS OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE IN ADULT CMV-SEROPOSITIVE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT: AN ENGLISH PAYER PERSPECTIVE. Value in Health. 21. S451–S452. 3 indexed citations

Oosthuyzen, Wilna, Wenjing Jia, Barry Sampson, et al.. (2018). Urinary Extracellular Vesicle Protein Profiling and Endogenous Lithium Clearance Support Excessive Renal Sodium Wasting and Water Reabsorption in Thiazide-Induced Hyponatremia. Kidney International Reports. 4(1). 139–147. 9 indexed citations

Jia, Wenjing, et al.. (2018). Clinical and Molecular Features of Thiazide-Induced Hyponatremia. Current Hypertension Reports. 20(4). 31–31. 16 indexed citations

Ware, James S., Louise V. Wain, Victoria E. Jackson, et al.. (2017). Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia. Journal of Clinical Investigation. 127(9). 3367–3374. 58 indexed citations

Barber, Jennifer S., Tricia M. McKeever, Sarah McDowell, et al.. (2014). A systematic review and meta‐analysis of thiazide‐induced hyponatraemia: time to reconsider electrolyte monitoring regimens after thiazide initiation?. British Journal of Clinical Pharmacology. 79(4). 566–577. 51 indexed citations

Glover, Mark, et al.. (2014). An audit of hyponatraemia in a large UK university teaching hospital. Endocrine Abstracts. 1 indexed citations

10.

Glover, Mark, G.L. Guthrie, José M. Brum, et al.. (2013). Effectiveness of 0.05% oxymetazoline (Vicks Sinex Micromist®) nasal spray in the treatment of objective nasal congestion demonstrated to 12 h post-administration by magnetic resonance imaging. Pulmonary Pharmacology & Therapeutics. 27(1). 121–126. 10 indexed citations

11.

Glover, Mark, James S. Ware, Amanda P. Henry, et al.. (2013). Detection of mutations inKLHL3andCUL3in families with FHHt (familial hyperkalaemic hypertension or Gordon's syndrome). Clinical Science. 126(10). 721–726. 40 indexed citations

12.

Glover, Mark & Kevin M. O’Shaughnessy. (2013). Molecular insights from dysregulation of the thiazide‐sensitive WNK/SPAK/NCC pathway in the kidney: Gordon syndrome and thiazide‐induced hyponatraemia. Clinical and Experimental Pharmacology and Physiology. 40(12). 876–884. 15 indexed citations

13.

Glover, Mark, et al.. (2011). Thiazide‐Induced Hyponatraemia: Epidemiology and Clues to Pathogenesis. Cardiovascular Therapeutics. 30(5). e219–26. 29 indexed citations

14.

Glover, Mark, et al.. (2010). A Single Amino Acid Substitution Makes WNK4 Susceptible to SB 203580 and SB 202190. PubMed. 4(1). 57–61. 1 indexed citations

15.

Glover, Mark, Annie Mercier Zuber, & Kevin M. O’Shaughnessy. (2010). Hypertension, Dietary Salt Intake, and the Role of the Thiazide-Sensitive Sodium Chloride Transporter NCCT. Cardiovascular Therapeutics. 29(1). 68–76. 47 indexed citations

16.

Glover, Mark & Kevin M. O’Shaughnessy. (2010). SPAK and WNK kinases: a new target for blood pressure treatment?. Current Opinion in Nephrology & Hypertension. 20(1). 16–22. 36 indexed citations

17.

Rafiqi, Fatema H., Annie Mercier Zuber, Mark Glover, et al.. (2010). Role of the WNK‐activated SPAK kinase in regulating blood pressure. EMBO Molecular Medicine. 2(2). 63–75. 218 indexed citations

18.

Glover, Mark, Annie Mercier Zuber, & Kevin M. O’Shaughnessy. (2009). Renal and Brain Isoforms of WNK3 Have Opposite Effects on NCCT Expression. Journal of the American Society of Nephrology. 20(6). 1314–1322. 43 indexed citations

19.

Chen, Lin, Mark Glover, Patrick G. Hogan, Anjana Rao, & Stephen C. Harrison. (1998). Structure of the DNA-binding domains from NFAT, Fos and Jun bound specifically to DNA. Nature. 392(6671). 42–48. 416 indexed citations

20.

Glover, Mark & Stephen C. Harrison. (1995). Crystal structure of the heterodimeric bZIP transcription factor c-Fos–c-Jun bound to DNA. Nature. 373(6511). 257–261. 608 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact